Introduction
Nanomedicine, the use of nanotechnology to diagnose or treat different pathologies, holds great promise to improve patient care. 1 Almost 75% of nanomedicines in clinical use consist of nanoparticles for drug delivery, 2 in which the main rationale is their capacity to improve the pharmacokinetics of the drug. Nanocarriers can enhance the stability and circulation time of the drug, increasing the amount that reaches the target organ and, therefore, decreasing the toxicity of chemotherapeutic drugs 1 . In the context of cancer, nanoparticles are able to reach tumor tissues due to the enhanced permeation and retention (EPR) effect. 3 The EPR effect is based on an increased extravasation of nanoparticles and macromolecules into the tumor due to leaky vasculature in the area, coupled with a decreased withdrawal capacity caused by the collapse of lymphatic vessels in solid tumors. Decorating the nanoparticle surface with polyethylene glycol (PEG) chains, in a process socalled PEGylation, inhibits protein adsorption on the nanoparticle surface. This hinders its recognition by macrophages and increases their circulation time in the bloodstream. This allows more nanoparticles to reach the tumor site. Additionally, active targeting strategies have also been developed by decorating the surface of nanocarriers with molecules that will induce their selective internalization in cancer cells. 4 This active targeting has been shown to increase the therapeutic efficacy of nanomedicines. 4 In recent years, stimuli-responsive nanomaterials have attracted great attention in the context of cancer treatment. 5 The possibility of inducing drug release only in the diseased site could potentially improve the efficacy of nanotherapeutics while decreasing the side-effects of systemic administration of anticancer drugs. Both internal (like pH or redox) 6, 7 and external (like light, magnetic field and ultrasound) [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] stimuli have been widely studied. However, ultrasound (US) appears especially interesting due to its non-invasiveness and high penetration capacity in living tissues. US offers the possibility to focus high frequency ultrasound deep into the body and the tumor mass, which would avoid unnecessary exposure to surrounding healthy tissues. 10 Mesoporous Silica Nanoparticles (MSNs) have also attracted much attention as drug carriers due to their high physicochemical stability and textural properties that would allow a high drug loading capacity. [19] [20] [21] [22] [23] In our group, we have recently reported an US-responsive MSN-based drug nanocarrier as an efficient proof of concept system for ondemand drug delivery. 24 However, the material presented in our previous work lacked some of the necessary characteristics needed for its use in a therapeutic application. For example, the surface of the material at physiological temperature is highly hydrophobic and the particles tend to aggregate. The lack of a PEG layer and active targeting moieties would also prevent them from reaching the desired target cancer cells. 25, 26 The objective of this work is to adapt our previous proof-of-concept material to a more viable design, according to the current knowledge in the field. Consequently, a series of chemical strategies were here developed to synthesize a PEGylated and modularly targeted US-responsive nanomaterial.
Experimental

Materials.
The following compounds were purchased from Sigma-Aldrich, and were used without further purification: ammonium nitrate, tetraethyl orthosilicate (TEOS), pyridine, methacrylic acid (MAA),
ether 2-(biotinylamino)ethane average M n 3800 Da (MAL-PEG-BIOTIN), poly(ethylene glycol) (N-hydroxysuccinimide 5-pentanoate) ether N′-(3-maleimidopropionyl)aminoethane average M n 4000 Da (MAL-PEG-NHS), 4-hydroxyazobenzene-2-carboxylic acid (HABA)/avidin kit, doxorubicin and fluorescein sodium salt. TetramethylrhodamineAzide (TAMRA-N3) was purchased from Thermo Fisher Scientific, and used without further purification. Dulbecco's Modified Eagle's Medium (DMEM), penicillin-streptomycin, and trypsin-EDTA were purchased from Invitrogen (Fisher Scientific, Spain). Fetal bovine serum (FBS) was purchased from Biowest (Labclinics, Spain).
Characterization techniques.
Characterization of the materials used in this study was performed by the following techniques: thermogravimetry and differential thermal analysis (TGA/DTA) in a PerkinElmer Pyris Diamond TG/DTA analyzer, with 10 ºC/min heating ramps, from 25 ºC to 600 ºC. Fourier transform infrared (FTIR) spectra were obtained in a Nicolet Nexus spectrometer (Thermo Fisher Scientific) equipped with a Smart Golden Gate attenuated total reflectance (ATR) accessory. Transmission electron microscopy (TEM) was carried out in a JEOL JEM 2100 instrument operated at 200 kV, equipped with a CCD camera (KeenView Camera). Phosphotungstic acid (PTA) was used to stain organic matter in the hybrid materials. N 2 adsorption was carried out on a Micromeritics ASAP 2010 instrument; surface area was obtained by applying the Brunauer-Emmett-Teller (BET) method to the isotherm and the pore size distribution was determined by the Barrett-Joyner-Halenda (BJH) method from the desorption branch of the isotherm. Mesopore diameter was obtained from the maximum of the pore size distribution curve. Z potential and hydrodynamic size of nanoparticles by Dynamic Light Scattering (DLS) were measured by means of a Zetasizer Nano ZS (Malvern Instruments) equipped with a 633 nm "red" laser. 1 
Synthesis of Mesoporous Silica Nanoparticles.
MSNs were synthesized by a condensation reaction of TEOS in the presence of CTAB template under dilute, basic conditions, as described elsewhere. 24 FITC-labeled MSNs were synthesized by reacting 1 mg of FITC with 2.2 μL APTES in 100 μL ethanol for 2 h. Then, the reaction mixture was added with TEOS to obtain the FITC-labeled MSNs, following the same protocol as before.
Synthesis of Ultrasound-Responsive Copolymer.
The monomer tetrahydropyranyl methacrylate (THPMA) was synthesized and purified as previously described. 24, 27 The random copolymer poly(2-(2-methoxyethoxy) ethyl methacrylate-co-2-tetrahydropyranyl methacrylate), with two functional ends and a monomer ratio 90:10 (MEO 2 MA:THPMA), was obtained by Reversible AdditionFragmentation Chain Transfer (RAFT) polymerization, adding CDTPA, ABCVA, MEO 2 MA and THPMA in a Schlenk flask. The flask was purged with N 2 and 8 mL dry DMF were added, with a catalytic amount of DIPEA to protect THPMA from degradation during the synthesis. Then, the flask was deoxygenated by three freeze-pump-thaw cycles. The reaction mixture was placed at 80 ºC under N 2 overnight with magnetic Please do not adjust margins Please do not adjust margins stirring. The obtained polymer was then precipitated and washed with diethyl ether. During synthesis optimization, different monomers/CDTPA ratios (Table S1 ) were used to obtain US-responsive polymers (PUS, Figure 1 ) with different molecular weights. Depending on the length of the polymers, each specific sample was named as follows: ca. 25000 Da (small, PUSS), ca. 50000 Da (medium, PUSM) and ca. 70000 Da (large, PUSL). The synthesized polymers presented yellow color due to the presence of the trithiocarbonate group from the RAFT agent, which confirmed the integrity of CDTPA through the polymerization reaction.
28,29
Preparation of PEGylated Ultrasound-Responsive Copolymer.
PEGylation of the obtained RAFT random copolymers was carried out by reacting MAL-PEG-OMe with the copolymer after the aminolysis of the trithiocarbonate group from CDTPA, which gives rise to a thiol moiety that reacted with the maleimide through a thiol-ene click reaction. This was performed as a one-pot reaction, by adding the MAL-PEG-OMe to the solution where the aminolysis was going to take place. Three PUS-PEG samples were obtained, PUS S -PEG, PUS M -PEG and PUS L -PEG, depending on the PUS used. The conditions to obtain PUS L -PEG were: 500 mg of PUS L and 100 mg of MAL-PEG-OMe were dissolved in 14 mL of dry DMF under inert atmosphere. The solution was deoxygenated by bubbling N 2 . Then, 500 µL of dry DMF containing 5 µL of hexylamine and 5 µL of TEA were added (to obtain PUS M -PEG and PUS S -PEG, the amount of MAL-PEG-OMe, hexylamine and TEA were adjusted to keep the same molar ratios as described above). The reaction took place overnight at room temperature, under N 2 and with magnetic stirring. Then, the polymers were precipitated in diethyl ether. After evaporating the ether, the solid was dissolved in ice-cold water. After heating the solution to 50 ºC, the precipitate formed was centrifuged and washed with preheated water. The purified polymer was then freezedried to obtain PUS-PEG.
Grafting PEGylated Ultrasound-Responsive Copolymer to MSNs.
Polymer grafting on the surface of MSNs to obtain HYBRID-PEG was performed as described previously. 24 Depending on the molecular weight of the polymeric gate being grafted, three different materials were obtained: HYBRID S -PEG, HYBRID M -PEG and HYBRID L -PEG. To prepare HYBRID L -PEG, 200 mg of PUS L -PEG were conjugated with APTES (5 µL) using DCC (4 mg) and NHS (2 mg) under N 2 in 3 mL dry DMF at room temperature, overnight, under magnetic stirring. Then, this sililated copolymer was reacted with previously dispersed MSNs (35 mg) in toluene at 80 ºC, overnight. The addition of the polymer to the MSNs suspension in toluene was performed in three steps, leaving 4 h gaps between additions to prevent polymerto-polymer condensation. The hybrid nanoparticles so obtained, HYBRID L -PEG, were then collected by centrifugation and washed with toluene, DMF (3 times), cold water (3 times) and ethanol. Then, the nanoparticles were dried under vacuum. To obtain HYBRID M -PEG and HYBRID S -PEG, the amount of APTES, DCC and NHS were adjusted to keep the same molar ratios as used above.
Preparation of Actively-targeted PEGylated UltrasoundResponsive system.
Synthesis of Biotin-targeted nanoparticles.
The polymer PUS L -PEG-BIOTIN was synthesized in a similar way to the one described for PUS-PEG, grafting MAL-PEG-BIOTIN to the US-responsive copolymer PUS L obtained by RAFT. Then, this polymer containing biotin was reacted with MSNs to obtain HYBRID L -PEG-BIOTIN, in a similar way as described above. In this case, half of the polymer chains had the moiety of interest, while the other half were PUS-PEG chains without further modification.
Synthesis of RGD-targeted nanoparticles.
The synthesis of the material HYBRID L -PEG-RGD was carried out in two steps: First, we prepared the hybrid containing DBCO moieties (HYBRIDL-PEG-DBCO), which was then reacted with an azide-functionalized peptide containing the RGD sequence: N3-Lys-Cys-Arg-Gly-Asp-Arg (RGD-N3). HYBRIDL-PEG-DBCO: The polymer dibenzocyclooctynepolyethilenglicol-maleimide, MAL-PEG-DBCO, was synthesized as follows (Scheme 1): 14 mg of DBCO-amine derivate were dissolved in the minimum amount possible of methylene chloride anhydrous. Under inert atmosphere, 10 µL of DIPEA were added and the mixture was stirred 30 minutes at room temperature (solution A). On the other hand, 40 mg of MAL-PEG-NHS were also dissolved in the minimum amount of dichloromethane under nitrogen atmosphere (solution B). Solution A was added dropwise over solution B and the resulted mixture was stirred overnight at 40 ºC. The methylene chloride was removed under vacuum and the resulting crude was purified by silica flash column chromatography using DCM:MeOH (30:1) as eluent. The final product was characterized by 1 H NMR, and the spectrum can be found in Figure S1 . Then, PUSL-PEG-DBCO was synthesized in a similar way as described for PUSL-PEG-BIOTIN, by grafting the synthesized MAL-PEG-DBCO to the US-responsive copolymer PUSL obtained by RAFT. This PUSL-PEG-DBCO was reacted with MSNs to obtain the HYBRIDL-PEG-DBCO similarly as described for the preparation of the hybrid containing biotin. HYBRID L -PEG-RGD: Initially, the peptide RGD-N 3 was synthetized following the standard solid-phase techniques using Fmoc-coupling chemistry (Scheme S2). Amino acids were added sequentially to build the peptide sequence on a solid resin. After the coupling of each amino acid, the solid resin was washed and deprotection of the last amino acid incorporated was performed to allow the coupling of the next one. The final functionalized Wang resin was treated with TFA/TIPS/H 2 O cleavage cocktail in order to afford a peptide crude that was purified by G-25 Sephadex column size exclusion chromatography. 1 H NMR spectrum can be found in Figure S2 .
To obtain RGD-modified particles, HYBRID L -PEG-RGD, 4 mg of HYBRID L -PEG-DBCO nanoparticles were reacted with RGD-N 3 (2 mg) in water at 4 ºC under magnetic stirring overnight. Then, the nanoparticles were collected by centrifugation and washed once with cold water and twice with preheated PBS (37 ºC).
Cargo loading and release.
Fluorescein loading was performed by dispersing the HYBRID-PEG material (10 mg) in a solution of fluorescein (100 mg) in PBS (5 mL) and stirring overnight at 4 ºC, since the polymeric gate will be open at that temperature. The medium was then heated to 37 ºC and the particles were collected by centrifugation. The loaded nanoparticles were extensively washed with PBS at 37 ºC. Doxorubicin loading was performed in a similar way using RGD-targeted nanoparticles: 4 mg of HYBRID L -PEG-RGD were loaded with doxorubicin in 2.5 mL of PBS containing 1 mg/mL of the drug at 4 ºC overnight.
Release experiments were performed as follows: Fluoresceinloaded materials dispersed in PBS were exposed to a commercial laboratory ultrasound device before starting the experiment (1.3 MHz, 100 W, 10 min, continuous wave (CW), conditions used in our previous work). 24 The experiment was carried out placing aliquots of suspensions of the loaded material in 12 well plate Transwell inserts (0.5 mL per insert), and adding 1.5 mL PBS to the outer volume of the well. At each time point, the external volume was collected and analyzed, and the well was filled with 1.5 mL of fresh PBS (to ensure sink conditions). The samples were measured by fluorimetry to determine the amount of fluorescein released (λ Ex : 490 nm; λ Em : 514 nm). Same procedure was carried out with samples without US exposure.
Cell culture experiments.
Cell culture experiments with HeLa cells were carried out to evaluate nanoparticle uptake by the cells, as well as cell viability when incubated with drug-loaded nanoparticles. HeLa cells were seeded in 24 well plates at a density of 20,000 cells per cm 2 24 h before the experiments were performed.
For the nanoparticle uptake experiments, cells were incubated with 200 µg/mL suspension of the nanoparticles (with or without the targeting moiety) in complete culture medium (DMEM with 10% FBS). The particles were incubated with the cells overnight, and then they were removed and the cells were washed with PBS to remove non-internalized nanoparticles. Cellular uptake was evaluated by fluorescence microscopy and flow cytometry. For the fluorescence microscopy experiments, cells were fixed with methanol containing 1 µg/mL DAPI to stain the cell nuclei, followed by three washing steps with PBS. Flow cytometry experiments were performed in 0.5 % trypan blue (in PBS) to remove any extracellular fluorescence due to non-internalized nanoparticles. For the cytotoxicity experiment, RGD-targeted nanoparticles (HYBRID L -PEG-RGD), loaded with doxorubicin were incubated with the cells overnight (100 µg/mL suspension). Then, the cells were rinsed with PBS, and half of the wells were exposed to ultrasound (using a physiotherapy device, New Pocket Sonovit, New Age Italia Srl, Italy) from the top of the well totally filled with culture medium (1 MHz, 3 W/cm 2 , 5 min, CW). The cells were then further incubated with 1 mL of complete culture medium per well. At different time points, cell viability was evaluated by Alamar Blue assay (Promega, Spain) following the manufacturer's instructions.
Results and Discussion
PEGylated Ultrasound-Responsive system
Recently, we have developed an ultrasound-responsive hybrid Mesoporous Silica Nanocarrier (HYBRID) capable of inducing cargo release when exposed to high frequency ultrasound. 24 That material was obtained by grafting a thermo-and ultrasound-responsive random copolymer, p(MEO 2 MA-co-THPMA), to the surface of MCM 41-type MSNs. Before ultrasound exposure, the copolymer shows an LCST lower than 37 ºC, so the polymer will be collapsed on the nanoparticle surface, capping the pore entrances and avoiding premature release of the cargo. Upon US exposure, the US-sensitive monomer THPMA will be cleaved, giving rise to hydrophilic methacrylic acid. This will induce an increase in the LCST of the polymer, which will irreversibly change to a coil-like conformation, opening the pore outlets and inducing cargo release at physiological temperature. 24, 30 However, that proof-of-concept material presents several problems when considering an in vivo scenario. First, the polymeric gate closes the pore entrances of the material when collapsing on its surface due to the thermoresponsive behavior of the polymer. 24 This implies that, when the material is closed, the surface is highly hydrophobic and the particles would therefore be likely to aggregate. Second, this material also lacks of any type of active targeting moieties, which are thought to be of great importance for the efficacy of nanotherapeutics. 4 Both problems could be potentially addressed by the attachment of PEG chains with a targeting agent to the exposed end of the polymer. The aim of this work is to adapt the proof-of-concept material previously reported to a more useful platform, PEGylated and actively targeted. However, the chemical strategies employed in our previous work would not enable to carry out this modification in an easy fashion, so novel methods need to be explored. A bifunctional US-responsive copolymer must be obtained to be able to attach a PEG molecule to it. That way, one functional end will be used to graft a PEG chain while the other one will be attached to the nanoparticle surface. The polymer described in our previous work, 24 which was obtained by Free Radical Polymerization (FRP), only presented one functional end, with a carboxylic acid provided by the initiator ABCVA. An US responsive copolymer with two different functional ends (PUS) has been here obtained changing the synthetic procedure from FRP to Reversible Addition-Fragmentation Chain Transfer (RAFT) polymerization by using a trithiocarbonate RAFT agent (CDTPA) that also presents a carboxylic acid (Figure 1 ). The monomer ratio was kept at 90:10 (MEO 2 MA:THPMA) according to our previous results. US-Responsive copolymers, PUS, with different molecular weights (M n ) were obtained (PUS S , PUS M and PUS L ) by modifying the monomers/RAFT agent ratio, 31 as shown in Table 1 . This allowed us to evaluate the effect of the molecular weight of the polymeric gate on the behavior of the final material. The aminolysis of the trithiocarbonate was carried out in the presence of a maleimide-modified PEG to graft it to the above RAFT copolymers. A one-pot thiol-ene click reaction took place, coupling the PEG chain to our US-responsive copolymers, 29 obtaining PUS-PEG polymers (Scheme 1) with different molecular weights ( Table 1) .
Scheme 1.
Representation of the synthetic procedure employed to obtain PUS-PEG.
After purification, the 1 H NMR spectra of the obtained copolymers ( Figure S3 ) confirms the PEG grafting (signal between 3.6 and 3.7 ppm). Table 1 shows an increase in the molecular weight of the copolymers after the PEGylation process in the same range as the molecular weights of the PEG chains being grafted. Furthermore, the absence of smaller polymer chains in the GPC chromatograms (data not shown) confirms the purification of the PEGylated copolymers from unreacted PEG chains. The US-responsiveness of the copolymer after conjugation with PEG was checked by monitoring the LCST behavior before and after ultrasound exposure. The results show that our PUS-PEG presents a LCST below 37 ºC in water before the application of US (Figure 2 ). This behavior implies that at physiological temperature the polymer will be collapsed on the nanoparticle surface, effectively capping the pores and preventing the premature release of the drug. After US application, the LCST is shifted to values above 45 ºC. This change is due to the cleavage of the hydrophobic THPMA and its conversion to hydrophilic methacrylic acid, which induces a change in the overall hydrophilicity of the p(MEO 2 MA-co-THPMA) block, displacing the LCST to a higher temperature.
24
The US-responsiveness of PUS-PEG was independent of its molecular weight (data not shown). This US-responsive behavior will provide the induced release capability in the final hybrid material. Once the US-responsiveness of PUS-PEG had been shown, it was then conjugated with APTES through its carboxylic acid (via DCC/NHS chemistry) and grafted to the surface of MSNs by condensation with the silanol groups of the silica particle, 24 as shown in Scheme 2. Thus, we obtained different PEGylated hybrid materials, HYBRID-PEG, as a function of the molecular weight of the PUS-PEG grafted, as can be seen in Table 2 . The organic matter percentage (determined by TGA) is similar (24-29 %) regardless of the molecular weight of the grafted polymer. However, significant differences can be found in the BET surface area, with decreasing values being obtained as the molecular weight of the polymers increased (Table 2, Figure S4 ). The different HYBRID-PEG materials prepared were loaded with fluorescein. The percentage of dye released in PBS at 37 ºC was measured after 20 h to test if the PEGylated USresponsive polymers effectively block the pore entrances of the nanoparticles. Data collected in Table 2 indicates that the molecular weight of the RAFT polymer was found to be crucial on capping the pores to block premature cargo release. Thus, higher molecular weight led to less release of fluorescein. This result is in good agreement with previous work reported in the literature, showing that the molecular weight of polymers used as capping agents of MSNs drastically affects their efficiency. 32 Longer polymer chains form larger aggregates when they collapse on the surface of the silica particle, acting as a more effective capping agent (Table 2 ). This is also in agreement with BET surface areas mentioned above for those same materials. It is worth noting that the M n needed to effectively cap the pores in this work is significantly higher than what we had seen in our preceding paper (around 28000 Da). 24 This different behavior can be explained by the change in the polymer synthetic method. RAFT polymerization allows a much better control over the polymerization reaction compared to to FRP. 33 Thus, the molecular weight distribution of the copolymers obtained by RAFT polymerization was narrower than that obtained by FRP (PDI values around 2). Therefore, for the same M n , the polymers obtained by FRP will present a significant percentage of polymer chains with a much larger size than the mean, which could have contributed to a better seal at the pore ends. According to these results, the hybrid material with the largest polymeric gate, HYBRID L -PEG, was selected for all further experiments.
Once HYBRID L -PEG had been selected, a more extensive characterization of the material further confirmed the successful grafting of PUS L -PEG on the material surface. Figure  3 shows the TEM micrographs of MSNs and HYBRID L -PEG, where the highly ordered mesoporous structure of the nanoparticles can be observed. Those same TEM micrographs of HYBRID L -PEG ( Figure 3) show a phosphotungstic acidstained layer on the nanoparticle surface, which was not present on MSNs, corresponding to the polymeric gate, and confirming the successful grafting of the polymer to the nanoparticle surface. The FTIR spectrum of HYBRID L -PEG (Figure 3) shows the typical bands of the polymer, between 1400 and 1800 cm -1 . The hydrodynamic diameter of HYBRID L -PEG obtained by DLS indicates a peak size of 250 nm, with Z potential values of -45 mV (hydrodynamic diameter of MSNs was 220 nm with a Z potential value of -21 mV). These data confirm the correct grafting of a PEGylated polymeric gate capable of blocking premature cargo release from the mesopores of the material at physiological temperature. 
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Please do not adjust margins mg/mL of nanoparticles) and kept at 37 ºC for 1 h without stirring,to be then evaluated under visible and ultraviolet (UV) light. HYBRID nanoparticles can be clearly observed at the bottom of the cuvette (better assessed by the fluorescence of nanoparticles under UV light), while HYBRID L -PEG nanoparticles remain much better dispersed. This enhancement in nanoparticle suspension stability was further confirmed by evaluating the hydrodynamic diameter of the PEGylated and the non-PEGylated system after different periods of time in suspension in 1 mM PBS ( Figure S5 ). NonPEGylated nanoparticles aggregated after 1 h in suspension, while the size of HYBRID L -PEG remained unmodified for 6 h. These results indicate that the stability of the nanoparticle suspension was greatly improved in the PEGylated system, which was one of the main aims of our approach. Besides, PEGylation will extend nanoparticle circulation time after injection in vivo, 25, 34 due to a slower withdrawal from the circulation by organs from the Mononuclear phagocyte system. Finally, the US-responsiveness of HYBRID L -PEG was evaluated performing fluorescein release experiments. The material should be capable of retaining the cargo at 37 ºC, and releasing it in response to the application of US as an external stimulus. Figure 5 shows that fluorescein release was greatly enhanced when US is applied on a loaded HYBRID L -PEG suspension. These results indicate that the US-induced cargo release capability is retained in this PEGylated material, and its behavior is comparable to that obtained in our previous work. 24 This US-responsive behavior would enable the cargo to be released mostly in the tumor environment, improving the safety and efficacy profile of the system. 
Targeted PEGylated Ultrasound-Responsive system
Heretofore, we have successfully obtained a PEGylated material that can trigger the release of its cargo when exposed to US. However, no active targeting strategy had been implemented to enhance the specificity of this material. To address the need for active targeting molecules, a different hybrid material was obtained by a similar process, but employing a PEG chain with biotin at one end (as targeting agent) and a maleimide at the other end (as coupling moiety), MAL-PEG-BIOTIN (Scheme 3). Consequently, the biotin moiety will be present on the end of the PEG chain attached to the polymeric gate on the nanoparticle surface. Biotin, also known as vitamin B7, can be employed as an active targeting agent due to the overexpression of biotin receptors by a variety of cancer cells. 35 While the TGA data did not allow us to estimate the amount of biotin in HYBRID L -PEG-BIOTIN ( Figure S4) , such quantification was possible through the HABA/Avidin test. The value obtained (2.13 nmol biotin/mg of nanoparticles) was in close agreement with the value expected from the organic matter % (determined by TGA) and the M n of the attached polymer.
Scheme 3. Synthetic procedure employed to obtain the PEGylated, biotin-targeted ultrasound-responsive material, HYBRIDL-PEG-BIOTIN.
An in vitro cellular uptake experiment was performed to test the efficacy of the biotin molecules exposed by our nanoparticles as active targeting agents. Incubation of nontargeted and targeted PEGylated nanoparticles (HYBRID L -PEG and HYBRID L -PEG-BIOTIN) with HeLa cells, which have been reported to overexpress biotin receptors, 36 shows a significantly increased cellular uptake of biotin-modified nanoparticles, as can be seen from fluorescence microscopy and flow cytometry data ( Figure 6 ). These results confirm the possibility to attach a targeting moiety to the external surface of our US-responsive nanocarrier, allowing a selective delivery to specific types of cancer cells. However, the chemical strategies employed to obtain our final system, limit the amount of targeting agents that can be conjugated to the PEG chain before it is coupled with the polymeric gate and then grafted to the particles. Any molecule possessing free amines, carboxylic acids, thiols or maleimides can interfere with the subsequent reactions, giving rise to undesired side-products, and limiting the presented approach. A modular device was designed to provide more versatility to our US-responsive system. Our approach consisted on conjugating a strained alkyne (the dibenzocyclooctyne or DBCO moiety) to a PEG molecule, which also presents a maleimide group in the other end, MAL-PEG-DBCO. This would allow carrying out the grafting process as already described (Scheme S1), and then coupling the desired targeting agent to the already prepared hybrid system, HYBRID L -PEG-DBCO, by using a copper-free alkyne-azidecyclo addition. The DBCO moiety will react with azide-functionalized molecules to yield a stable triazole linkage. Before grafting any targeting molecules, a coupling reaction with an azide-dye (TAMRA-N 3 ) was performed to ensure the presence and availability of the DBCO moiety in the material (Supporting Information). That way, sample color and/or fluorescence could be used to test if the click reaction has taken place. After reaction of HYBRID-PEG-DBCO with TAMRA-N 3 , sample fluorescence indicates a successful reaction with the dye (Figure S6 ). Same results were obtained with the intermediate products (MAL-PEG-DBCO, PUS L -PEG-DBCO). This demonstrates the correct coupling of DBCO and that it is available to react through click chemistry. On the other hand, no reaction with the dye took place in the materials not carrying DBCO. All of these results indicate that it is possible to graft an azide-modified molecule to our HYBRID L -PEG-DBCO. These data open the gate for endless easy modifications of the material, fine-tuning the targeting capacity of the system towards specific cell lines, once the US-responsive material has already been prepared. The versatility of this methodology has been tested by attaching a targeting agent to HYBRID L -PEG-DBCO and evaluating its cellular uptake. A peptide containing the RGD (Arg-Gly-Asp) sequence was used as the active targeting agent to be anchored to HYBRID L -PEG-DBCO. This sequence is selectively recognized by αvβ3 integrin receptor, and has been extensively studied as an active targeting agent for anticancer therapies. 37 Several functional groups present in this sequence (like amines and carboxylic acids) would impede the inclusion of this peptide in the PEGylated polymeric gate, due to incompatibility issues with the polymer grafting methodology above described. For this reason, the RGD sequence was attached to HYBRID L -PEG-DBCO by copper-free azide-alkyne cycloaddition using an azide-functionalized peptide, RGD-N 3 (Scheme S2) to obtain HYBRID L -PEG-RGD ( Figure 7 ).
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Please do not adjust margins sequence. 38 Figure 8 shows a significantly increased uptake in RGD-containing nanoparticles (HYBRID L -PEG-RGD). This result highlights the successful development of our modular strategy to obtain an actively-targeted material. Further, a competition assay with the addition of free RGD in the medium shows a decrease in the internalization of HYBRID L -PEG-RGD, indicating a receptor-mediated uptake mechanism. Finally, and since the material presented in this work is aimed for anticancer therapy, these actively-targeted nanoparticles must be able to kill cancer cells upon US exposure when loaded with a cytotoxic drug. According to the cellular uptake results, the targeted system (HYBRID L -PEG-RGD) was selected for our cytotoxicity experiment with drug-loaded nanoparticles. Doxorubicin-loaded HYBRID L -PEG-RGD nanoparticles were incubated with HeLa cells overnight. The cells were then washed with PBS to remove non-internalized nanoparticles, in order to try to only evaluate the effect on cell viability of nanoparticles that will release the drug within the cancer cell. Some of the cells were then exposed to ultrasound using a physiotherapy device, and cell viability was evaluated by Alamar Blue test over the next three days (Figure 9 ). Ultrasound itself was shown not to have any significant effect on cell viability. Ultrasound-exposed nanoparticles showed significantly higher cytotoxicity on HeLa cells than the nanoparticles not exposed to the stimulus, denoting the greater doxorubicin release upon US application. This further indicates that we have obtained a PEGylated, modularlytargeted, ultrasound responsive drug carrier with great potential in the field of cancer nanomedicine. Nanoparticle uptake by the target cancer cells will be enhanced by the addition of an active targeting molecule, and the external application of ultrasound in the tumor area will induce the release of the cytotoxic drug loaded in the nanoparticle, killing the cancer cells while decreasing the undesired side effects of chemotherapy. 
Conclusions
A PEGylated and targeted modular ultrasound-responsive nanocarrier based on Mesoporous Silica Nanoparticles has been successfully obtained. To prepare this material, we had to develop a new set of chemical strategies, since previously reported methods were not suitable to afford this versatile stimulus-responsive nanocarrier. First, a non-targeted PEGylated material possessing ultrasound-promoted cargo release was obtained and characterized. That PEGylated material showed increased stability in aqueous suspension when compared to its nonPEGylated control, which is of great interest for its biomedical application. By further modifying the material, a modular nanocarrier was obtained, in which any targeting agent could be easily attached to the final system through click chemistry. By taking advantage of that modularity of the material, RGD-decorated nanoparticles were obtained and demonstrated to induce enhanced cellular uptake. Drug-loaded RGD-targeted PEGylated nanoparticles were shown to produce significantly increased cancer cell killing when exposed to ultrasound.
